BioMarin Pharmaceutical Inc. (0HNC.L)
USD 66.73
(-0.75%)
USD 66.73
(-0.75%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.9 Billion USD | 14.25% |
| 2022 | 1.61 Billion USD | 17.2% |
| 2021 | 1.37 Billion USD | 2.96% |
| 2020 | 1.33 Billion USD | -0.62% |
| 2019 | 1.34 Billion USD | 14.34% |
| 2018 | 1.17 Billion USD | 9.71% |
| 2017 | 1.07 Billion USD | 18.15% |
| 2016 | 907.23 Million USD | 22.95% |
| 2015 | 737.88 Million USD | 18.77% |
| 2014 | 621.27 Million USD | 37.22% |
| 2013 | 452.74 Million USD | 10.72% |
| 2012 | 408.89 Million USD | 14.43% |
| 2011 | 357.33 Million USD | 16.78% |
| 2010 | 305.98 Million USD | 18.26% |
| 2009 | 258.74 Million USD | 6.05% |
| 2008 | 243.98 Million USD | 136.37% |
| 2007 | 103.22 Million USD | 36.77% |
| 2006 | 75.46 Million USD | 227.56% |
| 2005 | 23.04 Million USD | 56.86% |
| 2004 | 14.68 Million USD | 21.39% |
| 2003 | 12.1 Million USD | -13.07% |
| 2002 | 13.91 Million USD | 18.98% |
| 2001 | 11.69 Million USD | -38.23% |
| 2000 | 18.94 Million USD | 44.91% |
| 1999 | 13.07 Million USD | 587.89% |
| 1998 | 1.9 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 563.9 Million USD | 10.71% |
| 2024 Q1 | 509.35 Million USD | -0.27% |
| 2024 Q3 | 545.41 Billion USD | -1.17% |
| 2023 Q4 | 510.72 Million USD | 14.63% |
| 2023 FY | 1.84 Billion USD | 14.25% |
| 2023 Q2 | 450.91 Million USD | 0.05% |
| 2023 Q3 | 445.53 Million USD | -1.19% |
| 2023 Q1 | 450.69 Million USD | 9.86% |
| 2022 FY | 1.61 Billion USD | 17.2% |
| 2022 Q1 | 402.39 Million USD | 21.92% |
| 2022 Q2 | 410.67 Million USD | 2.06% |
| 2022 Q4 | 410.24 Million USD | 5.45% |
| 2022 Q3 | 389.05 Million USD | -5.26% |
| 2021 FY | 1.37 Billion USD | 2.96% |
| 2021 Q3 | 305.2 Million USD | -18.53% |
| 2021 Q2 | 374.63 Million USD | 2.4% |
| 2021 Q1 | 365.86 Million USD | 12.24% |
| 2021 Q4 | 330.06 Million USD | 8.14% |
| 2020 Q1 | 390.69 Million USD | 8.97% |
| 2020 FY | 1.33 Billion USD | -0.62% |
| 2020 Q2 | 331.51 Million USD | -15.15% |
| 2020 Q3 | 287.99 Million USD | -13.13% |
| 2020 Q4 | 325.97 Million USD | 13.19% |
| 2019 Q4 | 358.54 Million USD | -1.54% |
| 2019 Q1 | 311.56 Million USD | 11.99% |
| 2019 Q2 | 310.32 Million USD | -0.4% |
| 2019 FY | 1.34 Billion USD | 14.34% |
| 2019 Q3 | 364.14 Million USD | 17.34% |
| 2018 Q4 | 278.19 Million USD | -11.07% |
| 2018 Q3 | 312.81 Million USD | 6.46% |
| 2018 Q2 | 293.82 Million USD | 0.93% |
| 2018 Q1 | 291.11 Million USD | 3.12% |
| 2018 FY | 1.17 Billion USD | 9.71% |
| 2017 Q4 | 282.31 Million USD | 2.78% |
| 2017 Q2 | 261.14 Million USD | 2.92% |
| 2017 Q3 | 274.66 Million USD | 5.18% |
| 2017 Q1 | 253.73 Million USD | 7.54% |
| 2017 FY | 1.07 Billion USD | 18.15% |
| 2016 Q3 | 229.15 Million USD | -7.79% |
| 2016 Q4 | 235.94 Million USD | 2.96% |
| 2016 Q2 | 248.51 Million USD | 28.35% |
| 2016 Q1 | 193.61 Million USD | 7.63% |
| 2016 FY | 907.23 Million USD | 22.95% |
| 2015 Q1 | 170.45 Million USD | -7.88% |
| 2015 Q4 | 179.89 Million USD | 4.48% |
| 2015 FY | 737.88 Million USD | 18.77% |
| 2015 Q3 | 172.18 Million USD | -18.26% |
| 2015 Q2 | 210.64 Million USD | 23.58% |
| 2014 Q2 | 160.57 Million USD | 24.73% |
| 2014 Q4 | 185.03 Million USD | 25.94% |
| 2014 FY | 621.27 Million USD | 37.22% |
| 2014 Q1 | 128.73 Million USD | 5.3% |
| 2014 Q3 | 146.92 Million USD | -8.5% |
| 2013 Q1 | 107.42 Million USD | 1.92% |
| 2013 Q4 | 122.25 Million USD | 12.34% |
| 2013 FY | 452.74 Million USD | 10.72% |
| 2013 Q3 | 108.82 Million USD | -4.75% |
| 2013 Q2 | 114.24 Million USD | 6.34% |
| 2012 Q1 | 99.54 Million USD | 15.31% |
| 2012 FY | 408.89 Million USD | 14.43% |
| 2012 Q4 | 105.4 Million USD | 1.84% |
| 2012 Q3 | 103.49 Million USD | 3.04% |
| 2012 Q2 | 100.44 Million USD | 0.91% |
| 2011 Q2 | 91.36 Million USD | 3.05% |
| 2011 Q1 | 88.66 Million USD | 9.26% |
| 2011 FY | 357.33 Million USD | 16.78% |
| 2011 Q4 | 86.32 Million USD | -5.11% |
| 2011 Q3 | 90.98 Million USD | -0.42% |
| 2010 FY | 305.98 Million USD | 18.26% |
| 2010 Q1 | 67.54 Million USD | -4.0% |
| 2010 Q2 | 77.54 Million USD | 14.82% |
| 2010 Q3 | 79.74 Million USD | 2.83% |
| 2010 Q4 | 81.14 Million USD | 1.75% |
| 2009 FY | 258.74 Million USD | 6.05% |
| 2009 Q4 | 70.35 Million USD | 6.86% |
| 2009 Q1 | 59.61 Million USD | -31.95% |
| 2009 Q2 | 62.93 Million USD | 5.57% |
| 2009 Q3 | 65.83 Million USD | 4.6% |
| 2008 Q2 | 54.58 Million USD | 26.32% |
| 2008 FY | 243.98 Million USD | 136.37% |
| 2008 Q1 | 43.2 Million USD | 9.03% |
| 2008 Q4 | 87.61 Million USD | 49.55% |
| 2008 Q3 | 58.58 Million USD | 7.33% |
| 2007 Q2 | 24.32 Million USD | 29.94% |
| 2007 Q1 | 18.72 Million USD | 1.73% |
| 2007 Q4 | 39.63 Million USD | 92.88% |
| 2007 FY | 103.22 Million USD | 36.77% |
| 2007 Q3 | 20.54 Million USD | -15.54% |
| 2006 Q4 | 18.4 Million USD | -17.53% |
| 2006 Q2 | 22.66 Million USD | 87.44% |
| 2006 Q1 | 12.09 Million USD | 48.4% |
| 2006 FY | 75.46 Million USD | 227.56% |
| 2006 Q3 | 22.31 Million USD | -1.53% |
| 2005 Q2 | 3.14 Million USD | -27.28% |
| 2005 FY | 23.04 Million USD | 56.86% |
| 2005 Q4 | 8.14 Million USD | 9.87% |
| 2005 Q3 | 7.41 Million USD | 135.55% |
| 2005 Q1 | 4.32 Million USD | -59.13% |
| 2004 FY | 14.68 Million USD | 21.39% |
| 2004 Q2 | 3.95 Million USD | 0.0% |
| 2004 Q3 | 146 Thousand USD | -96.3% |
| 2004 Q4 | 10.59 Million USD | 7154.79% |
| 2004 Q1 | - USD | 100.0% |
| 2003 Q1 | 3.49 Million USD | 11.52% |
| 2003 FY | 12.1 Million USD | -13.07% |
| 2003 Q4 | -15.59 Million USD | 0.0% |
| 2003 Q3 | - USD | -100.0% |
| 2003 Q2 | 12.1 Million USD | 246.11% |
| 2002 Q1 | 3.79 Million USD | 325.59% |
| 2002 Q3 | 3.56 Million USD | 4.27% |
| 2002 FY | 13.91 Million USD | 18.98% |
| 2002 Q4 | 3.13 Million USD | -12.16% |
| 2002 Q2 | 3.42 Million USD | -9.73% |
| 2001 Q2 | 3.35 Million USD | -33.27% |
| 2001 Q4 | 891 Thousand USD | -74.27% |
| 2001 Q3 | 3.46 Million USD | 3.19% |
| 2001 Q1 | 5.02 Million USD | 1.53% |
| 2001 FY | 11.69 Million USD | -38.23% |
| 2000 Q2 | 4.61 Million USD | -4.84% |
| 2000 Q1 | 4.85 Million USD | 8.52% |
| 2000 Q3 | 4.52 Million USD | -2.08% |
| 2000 FY | 18.94 Million USD | 44.91% |
| 2000 Q4 | 4.95 Million USD | 9.58% |
| 1999 Q3 | 3.9 Million USD | 44.44% |
| 1999 Q2 | 2.7 Million USD | -12.9% |
| 1999 Q4 | 4.47 Million USD | 14.62% |
| 1999 FY | 13.07 Million USD | 587.89% |
| 1999 Q1 | 3.1 Million USD | 0.0% |
| 1998 FY | 1.9 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Editas Medicine, Inc. | -99.52 Million USD | 2013.403% |
| Dynavax Technologies Corporation | 182.11 Million USD | -945.686% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | -263.609% |
| Perrigo Company plc | 1.68 Billion USD | -13.328% |
| Illumina, Inc. | 2.74 Billion USD | 30.599% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 87.491% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 20007.715% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 92.82% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 63.65% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -18864.071% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 83.149% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 9767.354% |
| Waters Corporation | 1.76 Billion USD | -8.13% |
| Biogen Inc. | 7.3 Billion USD | 73.921% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 4301.593% |
| Evolus, Inc. | 140.52 Million USD | -1255.174% |
| Adicet Bio, Inc. | -6.09 Million USD | 31329.452% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -12772.597% |
| bluebird bio, Inc. | -4.03 Million USD | 47354.888% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -2506.337% |
| FibroGen, Inc. | 128.9 Million USD | -1377.357% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 45.04% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 6210.09% |
| Homology Medicines, Inc. | -7.22 Million USD | 26443.505% |
| Geron Corporation | -123.5 Million USD | 1641.964% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | -25.462% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | -426.026% |
| Myriad Genetics, Inc. | 476.4 Million USD | -299.742% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 652282.192% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 577.533% |
| Zoetis Inc. | 5.83 Billion USD | 67.357% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -630486.755% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 12.203% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 77.874% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 628605.611% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | -144.616% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 608525.559% |
| Verastem, Inc. | -62 Thousand USD | 3071667.742% |
| Nektar Therapeutics | 53.47 Million USD | -3461.038% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | -678.773% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 2334.759% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | -74.235% |
| OPKO Health, Inc. | 318.12 Million USD | -498.62% |
| Exelixis, Inc. | 1.75 Billion USD | -8.347% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | -3.084% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | -300.167% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 2.21 Million USD | -85876.163% |
| Imunon, Inc. | -720 Thousand USD | 264594.274% |
| Blueprint Medicines Corporation | 236.58 Million USD | -704.945% |
| Insmed Incorporated | 239.63 Million USD | -694.697% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | -199.01% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -10895.854% |
| TG Therapeutics, Inc. | 219.1 Million USD | -769.148% |
| Incyte Corporation | 3.44 Billion USD | 44.651% |
| Emergent BioSolutions Inc. | 343.9 Million USD | -453.757% |